Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company dedicated to transforming medicines for better patient outcomes, has announced that its management team will take part in several upcoming investor conferences. These events will provide a valuable opportunity for the company to engage with investors and share its strategic vision along with innovative solutions.
Details of the Upcoming Conferences
The upcoming investor conferences are as follows:
- 2024 Wells Fargo Healthcare Conference: A fireside chat is scheduled for September 4 at 3:45 p.m. ET.
- Morgan Stanley 22nd Annual Global Healthcare Conference: A fireside chat will take place on September 6 at 10:00 a.m. ET.
- H.C. Wainwright 25th Annual Global Investment Conference: A fireside chat is set for September 11 at 11:30 a.m. ET.
These conferences offer a platform for Avadel's leadership to provide insights and updates on the company's progress and future plans.
Live Webcasts and Recordings
Avadel Pharmaceuticals intends to provide live webcasts of these events, along with archived recordings. All presentations will be accessible on Avadel’s Investor Relations website for 90 days following each conference. Stakeholders and interested individuals are encouraged to tune in, as these discussions will explore the company’s innovations and growth strategies.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc is committed to developing transformative medicines. The company focuses on creating innovative solutions that address the various challenges patients face with current treatment options. One of Avadel's key products, LUMRYZ™, is distinguished as the first and only once-at-bedtime oxybate approved by the U.S. Food and Drug Administration (FDA) for treating cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. This achievement underscores Avadel's dedication to enhancing patient outcomes through innovative pharmaceutical advancements.
Commitment to Innovation
Through its research and development initiatives, Avadel Pharmaceuticals is dedicated to formulating medications that prioritize both effectiveness and patient adherence. The company's ongoing investment in innovation aims to meet unmet medical needs and improve the quality of life for patients.
Contact Information
For inquiries or additional information, investors and media representatives can reach out to the following contacts:
Investor Contact
Courtney Mogerley
Precision AQ
Email: Courtney.Mogerley@precisionAQ.com
Phone: (212) 698-8687
Media Contact
Lesley Stanley
Real Chemistry
Email: lestanley@realchemistry.com
Phone: (609) 273-3162
Frequently Asked Questions
What is Avadel Pharmaceuticals focusing on in its upcoming conferences?
Avadel Pharmaceuticals plans to present its strategic vision and innovative solutions, particularly highlighting its transformative medicines.
When will Avadel participate in the Wells Fargo Healthcare Conference?
The company is set to participate in the Wells Fargo Healthcare Conference on September 4 at 3:45 p.m. ET.
Where can I watch the webcasts of the conferences?
The live webcasts and archived recordings will be available on Avadel's Investor Relations website for 90 days after each conference.
What is LUMRYZ™?
LUMRYZ™ is Avadel's commercial product, recognized as the first and only once-at-bedtime oxybate approved by the FDA for treating symptoms related to narcolepsy.
How can I contact Avadel Pharmaceuticals for investor relations?
For investor inquiries, you can reach Courtney Mogerley via email at Courtney.Mogerley@precisionAQ.com or by phone at (212) 698-8687.